A Phase 4 interventional study of Intracavitary Manual Lymphatic Drainage and Conventional treatment in Lymphatic Diseases, sponsored by Universidad Europea de Madrid. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-23.
Sponsored by Universidad Europea de Madrid · Phase 4, Interventional, and Treatment
The aim of this study was to determine the effectiveness of Intracavitary Manual Lymphatic Drainage (IMLD) in the reduction of the perineal trauma and the symptoms of vaginal edema, the prevention of complications during the expulsive and the improvement in the postpartum recovery, compared to conventional treatment during the gestation, in women with the second partum. The weekly treatment is performed from the 25th gestational week in women with vulvar edema.
47 studies on the registry are indexed under Lymphatic Diseases; 11 are open to participants now.
This study's enrollment of 49 is above the median of 30 across 31 interventional studies indexed under Lymphatic Diseases.
Browse Lymphatic Diseases studies →Universidad Europea de Madrid is the lead sponsor of 94 studies on the registry; 22 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Intracavitary Manual Lymphatic Drainage technique.
Other: Intracavitary Manual Lymphatic Drainage
Conventional treatment active comparator
Other: Conventional treatment
Pain intensity assessed by the Visual Analogue Scale
Time frame: 5 weeks
No study locations are listed for this record.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad Europea de Madrid